
January 29, 2025
BlinkLab Limited (ASX:BB1) (“BlinkLab”, or the “Company”) an innovative digital healthcare company leveraging smartphones, computer vision, Artificial Intelligence (“AI”), and Machine Learning (“ML”) to diagnose neurodevelopmental conditions such as autism and ADHD, is pleased to release its Appendix 4C and Quarterly Activity Report for the period ended 31 December 2024 (the “Quarter”).
Highlights
- BlinkLab initiated its FDA registrational study, which aims to revolutionise the diagnostics and care for autism, making it more accessible and reliable.
- The initial phase will recruit up to 100 participants (children aged between 2-11 years old), with the main study recruiting up to 1,000 subjects.
- Four clinical sites have been selected, with six additional sites to be added; the sites are spread across the US to ensure diversity of the population.
- Final results are expected by the end of CY 2025 and will be used for the 510(k) Food and Drug Administration (“FDA”) approval.
- BlinkLab received positive feedback from a Pre-Submission meeting with the US Federal Drug Administration (“FDA”) regarding the regulatory pathway for BlinkLab Dx 1 diagnostic app.
- Final results from the pivotal autism study (announced in November of 2024) bolster confidence that BlinkLab Dx 1 will surpass the accuracy parameters that are required for regulatory approval in the upcoming FDA registration trial.
- BlinkLab and Monash University have partnered on the large-scale Monash Autism-ADHD Genetics and Neurodevelopment (“MAGNET”) study, which aims to conduct deep phenotyping in children on the autism spectrum, with ADHD, or both. The study will also work towards further improvements to BlinkLab’s Machine Learning (“ML”) algorithm to better distinguish between autism- and ADHD-specific clinical features.
- As at 31 December 2024, the Company had a cash balance of A$4.4 million.
Following the positive outcome from the recent FDA pre-submission meeting, as well as positive final data from the pivotal preliminary study (ASX Announcement 19 November 2024), BlinkLab is confident in the success of its registrational study, as well as the subsequent 510(k) regulatory approval for our first diagnostic tool for autism, called “Blinklab Dx 1”.
US FDA Registrational Study in Autism Now Underway
The FDA registrational study program will consist of a pilot study, followed by the primary study. The pilot study will recruit up to 100 participants (children aged between 2-11 years) and will continue into a registrational study, which will be conducted with up to 1,000 subjects across ten clinical sites in the US. The pilot study will be used to train the investigators and personnel at clinical sites, as well as to test the procedures of subject screening and data collection. These steps are part of BlinkLab’s considered strategy for mitigating risk leading up to the main FDA study and are aimed at ensuring the highest quality of data and diagnostic accuracy of the BlinkLab tests.
Click here for the full ASX Release
This article includes content from Blinklab Limited, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.
BB1:AU
The Conversation (0)
25 September 2024
BlinkLab Limited
Revolutionising Mental Health Care Through Mobile Solutions
Revolutionising Mental Health Care Through Mobile Solutions Keep Reading...
01 May
Successful Placement of A$7.66M to Underpin Growth Strategy
BlinkLab Limited (BB1:AU) has announced Successful Placement of A$7.66M to Underpin Growth StrategyDownload the PDF here. Keep Reading...
29 April
Trading Halt
BlinkLab Limited (BB1:AU) has announced Trading HaltDownload the PDF here. Keep Reading...
27 April
Quarterly Activities/Appendix 4C Cash Flow Report
BlinkLab Limited (BB1:AU) has announced Quarterly Activities/Appendix 4C Cash Flow ReportDownload the PDF here. Keep Reading...
31 March
BlinkLab Surpasses Key Milestone in Pivotal U.S. Trial
BlinkLab Limited (BB1:AU) has announced BlinkLab Surpasses Key Milestone in Pivotal U.S. TrialDownload the PDF here. Keep Reading...
30 March
Trading Halt
BlinkLab Limited (BB1:AU) has announced Trading HaltDownload the PDF here. Keep Reading...
17 October
Tech Weekly: Broadcom and OpenAI Sign Deal, AMD and Oracle Announce Partnership
This week was marked by strong, event-driven volatility across the tech sector. Market moves were shaped by artificial intelligence (AI) infrastructure announcements, semiconductor earnings, signals of macroeconomic stress and escalating tensions between the US and China. Effects of the US... Keep Reading...
16 October
AF2 Capital Corp. Enters into Letter of Intent for Reverse-Takeover Transaction with EverKind Inc.
AF2 Capital Corp. (TSXV: AF.P) ("AF2" or the "Company") is pleased to announce it has entered into a non-binding letter of intent dated October 14, 2025 (the "LOI") with EverKind Inc. ("EverKind"), an AI-powered emotional wellness platform, which sets forth, in general terms, the basic terms and... Keep Reading...
08 October
AI Market Update: Q3 2025 in Review
Q3 solidified artificial intelligence (AI) as the central growth engine within the tech sector, driving the Nasdaq Composite (INDEXNASDAQ:.IXIC) and S&P 500 (INDEXSP:.INX) to new heights. AI-focused stocks dominated market gains during the period, while venture capital funding for AI startups in... Keep Reading...
26 September
Tech Weekly: Tech Stocks React to Fed, AI News and Geopolitical Tensions
This week’s market action reflected renewed caution amid evolving signals from the US Federal Reserve, with tech stocks facing pressure from shifting interest rate expectations and renewed overvaluation concerns. Artificial intelligence (AI) heavyweight NVIDIA (NASDAQ:NVDA) announced a US$100... Keep Reading...
26 September
Syntheia Signs Definitive Agreement for Call Center Acquisition
Syntheia Corp. (CSE: SYAI) ("Syntheia" or the "Company") (syntheia.ai), today announced that it has entered into an amended and restated agreement dated September 25, 2025 (the "Restated Agreement") with Call Center Guys Inc. ("CCG"), to amend and restate the terms of an asset purchase agreement... Keep Reading...
Latest News
Latest Press Releases
Related News
TOP STOCKS
American Battery4.030.24
Aion Therapeutic0.10-0.01
Cybin Corp2.140.00